ArticleNPJ precision oncology2018
Case study: patient-derived clear cell adenocarcinoma xenograft model longitudinally predicts treatment response.
Article in NPJ precision oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Pooled it
- Personalizing chemotherapy drug selection using a novel transcriptomic chemogram.PLoS computational biology · 2025Article
- Exploring bone-tumor interactions through 3DJournal of bone oncology · 2025Review
- Biomarkers and immunotherapy in endometrial cancer: mechanisms and clinical applications.Frontiers in immunology · 2025Review
- Comparative analysis of response to treatments and molecular features of tumor-derived organoids versus cell lines and PDX derived from the same ovarian clear cell carcinoma.Journal of experimental & clinical cancer research : CR · 2023Article
- Generation, evolution, interfering factors, applications, and challenges of patient-derived xenograft models in immunodeficient mice.Cancer cell international · 2023Review
- The future of patient-derived xenografts in prostate cancer research.Nature reviews. Urology · 2023Review
- Evolution-Informed Strategies for Combating Drug Resistance in Cancer.International journal of molecular sciences · 2023Review
- Patient-derived xenografts or organoids in the discovery of traditional and self-assembled drug for tumor immunotherapy.Frontiers in oncology · 2023Review
- The Mutational Landscape of Cancer's Vulnerability to Ionizing Radiation.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Article
- Multivalent state transitions shape the intratumoral composition of small cell lung carcinoma.Science advances · 2022Article
- Functional Precision Oncology: The Next Frontier to Improve Glioblastoma Outcome?International journal of molecular sciences · 2022Review
- Personalized Treatment of Advanced Gastric Cancer Guided by the MiniPDX Model.Journal of oncology · 2022Article
- Identification of distinct tumor cell populations and key genetic mechanisms through single cell sequencing in hepatoblastoma.Communications biology · 2021Article
- Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidatesfor targeted treatment.Nature communications · 2021Article
- Current methods in translational cancer research.Cancer metastasis reviews · 2021Review
- Review
- A Proof of Concept for Biomarker-Guided Targeted Therapy against Ovarian Cancer Based on Patient-Derived Tumor Xenografts.Cancer research · 2020Article
- Zebrafish patient avatars in cancer biology and precision cancer therapy.Nature reviews. Cancer · 2020Review
- Zebrafish Avatars towards Personalized Medicine-A Comparative Review between Avatar Models.Cells · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
Abstract
There has been little progress in the use of patient-derived xenografts (PDX) to guide individual therapeutic strategies. In part, this can be attributed to the operational challenges of effecting successful engraftment and testing multiple candidate drugs in a clinically workable timeframe. It also remains unclear whether the ancestral tumor will evolve along similar evolutionary trajectories in its human and rodent hosts in response to similar selective pressures (i.e., drugs). Herein, we combine a metastatic clear cell adenocarcinoma PDX with a timely 3 mouse
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.